{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:36:04Z","timestamp":1788478564899,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are widely used in the treatment of various tumor types. ICIs kill tumor cells by activating the body\u2019s immune function. As this action is nonspecific, it inevitably triggers immune-related adverse events (irAEs), which can affect virtually all organs. Although the renal toxicity associated with ICIs such as pembrolizumab, nivolumab, and ipilimumab has been studied, research on domestically developed Chinese ICIs, including camrelizumab, sintilimab, tislelizumab, and toripalimab, remains limited. This paper presents the case of a lung cancer patient who developed stage 3 acute kidney injury (AKI) requiring dialysis following treatment with sintilimab. A literature review suggests that this is likely the second documented case of AKI necessitating dialysis after a single dose of sintilimab. Early recognition of irAEs, identification of risk factors, regular monitoring, steroid administration, and supportive care are crucial for improving patient outcomes. It should be emphasized that the tumor benefits of ICI therapy outweigh the risks of ICI-induced renal injury. In such cases, ICI treatment should not be discontinued or delayed, except in rare circumstances such as acute renal failure. When AKI occurs, healthcare professionals must be familiar with renal-related irAEs in order to facilitate the effective diagnosis and management of this increasingly common renal complication.<\/jats:p>","DOI":"10.3389\/fonc.2025.1632740","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:43Z","timestamp":1760933683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies"],"prefix":"10.3389","volume":"15","author":[{"given":"Bin","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066","article-title":"Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3760\/cma.j.cn114015-20220923-00869","article-title":"Analysis of the occurrence and influencing factors of immune checkpoint inhibitor-related kidney injury","volume":"25","author":"Nan","year":"2023","journal-title":"Adverse Drug Reactions J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-1533.2023.01.017","article-title":"Identification, management and pharmaceutical care of a diabetes mellitus patient with immune-related adverse reaction","volume":"44","author":"Chunhui","year":"2023","journal-title":"Shanghai Med Pharm J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn114015-20201207-01218","article-title":"Sintilimab causes multi-organ toxicity","volume":"23","author":"Yiling","year":"2021","journal-title":"Adverse Drug Reactions J"},{"key":"B6","volume-title":"Meta-analysis of nephrotoxicity in patients with solid tumors treated with anti-PD-1\/PD-L1 monoclonal antibodies","author":"Han","year":"2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3969\/j.issn.1001\u20439057.2022.01.006","article-title":"Analysis of risk factors related to acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"39","author":"Mingsu","year":"2022","journal-title":"J Clin Internal Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3760\/cma.j.cn115455-20220224-00124","article-title":"Clinical and pathologic manifestations of immune checkpoint inhibitor-associated acute kidney injury","volume":"45","author":"Qiyuan","year":"2022","journal-title":"Chin J Postgraduates Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0252978","DOI":"10.1371\/journal.pone.0252978","article-title":"Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study","volume":"16","author":"Koks","year":"2021","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01039-5","article-title":"Nephrotoxicity in patients with solid tumors treated with anti-PD-1\/PD-L1 monoclonal antibodies: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2021","journal-title":"Investigational New Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunotherapy Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11071187","article-title":"Renal Complications related to checkpoint inhibitors: diagnostic and therapeutic Strategies","volume":"11","author":"Belliere","year":"2021","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441217-20220221-00115","article-title":"Clinical features of acute kidney injury in patients receiving immune checkpoint inhibitors for oncology","volume":"38","author":"Ye","year":"2022","journal-title":"Chin J Nephrology"},{"key":"B15","volume-title":"Chinese Society of Clinical Oncology (CSCO) guidelines for the management of immune checkpoint inhibitor-related toxicity","author":"Shukui","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system","volume":"21","author":"Pico de Coa\u00f1a","year":"2015","journal-title":"Trends Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-8157.2023.02.009","article-title":"Literature analysis of adverse drug reaction induced by sintilimab","volume":"20","author":"Miao-Miao","year":"2023","journal-title":"Chin J Drug Appl Monitoring"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrology: JASN"},{"key":"B21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12885-020-07251-z","article-title":"Safety and efficacy of sintilimab combined with oxaliplatin\/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02738-x","article-title":"Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study","volume":"70","author":"Jiang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00386-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12385","article-title":"Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)","volume":"42","author":"Shi","year":"2022","journal-title":"Cancer Commun (London England)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ (Clinical Res ed)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353339","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-0848-y","article-title":"Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report","volume":"19","author":"Koda","year":"2018","journal-title":"BMC Nephrology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919875549","article-title":"The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma","volume":"11","author":"Marco","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw382","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrology Dialysis Transplantation: Off Publ Eur Dialysis Transplant Assoc \u2013 Eur Renal Assoc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"Curr Drug Safety"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-009-9608-z","article-title":"NGAL: a biomarker of acute kidney injury and other systemic conditions","volume":"42","author":"Soni","year":"2010","journal-title":"Int Urol Nephrology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1632740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:51Z","timestamp":1760933691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1632740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":38,"alternative-id":["10.3389\/fonc.2025.1632740"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1632740","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1632740"}}